A pivotal study published in 1993 compared CHOP to several other chemotherapy regimens (e.g.
However, in Germany in 2012, bendamustine has displaced [R-]CHOP to become the first line treatment of choice for indolent lymphoma (a less aggressive subset of non-Hodgkin lymphoma) [REF].